| Literature DB >> 12752181 |
Abstract
Oral isotretinoin revolutionized acne treatment when it was introduced in 1982 in the USA. However, its use was restricted to patients with severe nodulocystic acne. Today its use worldwide has expanded to treat also patients with less severe but scarring acne who are responding unsatisfactorily to conventional therapies. These recommendations assess the potential for use of oral isotretinoin as a safe and effective treatment for severe nodulocystic acne unresponsive to conventional therapy, and acne of any severity that causes scarring or is associated with psychological distress.Entities:
Mesh:
Substances:
Year: 2003 PMID: 12752181 DOI: 10.1046/j.1440-0960.2003.00653.x
Source DB: PubMed Journal: Australas J Dermatol ISSN: 0004-8380 Impact factor: 2.875